Full-Time

Director AI Engineering and Enablement

Posted on 7/10/2026

Deadline 8/8/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$193k - $233.9k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

Madison, NJ, USA + 1 more

More locations: Princeton, NJ, USA

Hybrid

Hybrid work requires at least 50% on-site presence at the assigned facility.

Bachelor's, Master's

Category
Engineering Management (1)
Required Skills
Microsoft Azure
Python
React.js
Docker
Version Control
Microservices
AWS
LangGraph
Observability
LangChain
Google Cloud Platform

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Requirements
  • A Bachelor’s or Master’s degree in Computer Science, Engineering, or a related field.
  • At least 7 years of experience in software or artificial intelligence engineering.
  • At least 3 years of experience leading technical teams.
  • Proven experience developing and deploying enterprise applications in cloud environments using AWS, Azure, or Google Cloud Platform.
  • Advanced skills in Python and React, with familiarity with modern generative artificial intelligence frameworks such as LangChain and LangGraph.
  • Strong understanding of the artificial intelligence application lifecycle, security, compliance, and performance optimization.
  • Excellent communication, leadership, and project management skills.
Responsibilities
  • Lead the architecture, design, and implementation of scalable enterprise artificial intelligence applications.
  • Drive the technical strategy for generative artificial intelligence solutions, ensuring robust integration, security, and performance across the organization.
  • Architect, design, and build end-to-end generative artificial intelligence applications.
  • Define solution architectures using AWS, Azure, and Google Cloud Platform for scalability, reliability, and security.
  • Present and propose technical solutions that fit requirements.
  • Plan and coordinate project deliveries to meet timelines and business needs.
  • Develop core features and infrastructure, including production-grade code in Python, React, and other languages as needed.
  • Lead implementation of software engineering practices including modularity, version control, continuous integration and continuous delivery, and automated testing.
  • Perform code and architecture reviews to ensure robust, maintainable, and high-performing solutions.
  • Drive adoption of engineering best practices across the organization.
  • Set standards for thorough and clear documentation of architectures, processes, and code.
  • Directly manage a team of senior and junior engineers, including hiring, onboarding, and day-to-day activities.
  • Provide technical mentorship and foster a culture of innovation, learning, and inclusiveness.
  • Set clear objectives, track progress, and conduct regular performance reviews.
  • Research, design, and implement agentic artificial intelligence solutions using frameworks such as LangChain and LangGraph.
  • Build autonomous generative artificial intelligence agents capable of reasoning, multi-step workflows, and tool usage.
  • Optimize agent performance, reliability, and compliance for enterprise production.
  • Evaluate emerging artificial intelligence techniques, tools, and frameworks and make strategic recommendations.
  • Champion artificial intelligence and engineering best practices and foster continuous learning through technical talks and workshops.
  • Develop intuitive user interfaces in React and integrate front ends with back-end application programming interfaces and artificial intelligence models.
  • Collaborate with user experience and user interface teams to drive adoption and usability of artificial intelligence applications.
  • Maintain and evolve RESTful application programming interfaces and microservices architecture.
  • Deploy, monitor, and maintain artificial intelligence applications using cloud-native infrastructure, containers, continuous integration and continuous delivery, and observability tools.
  • Oversee cloud resources to optimize cost and performance.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $12.97 billion, and guidance rose to $49 billion-$50 billion.
  • Growth portfolio reached nearly 60% of revenue, led by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi.
  • Houston expansion should add 500 jobs and bolster supply reliability before 2030 launches.

What critics are saying

  • Eliquis loses U.S. exclusivity April 1, 2028, triggering immediate multi-source generic erosion.
  • Opdivo faces 2028 patent loss, exposing BMS to biosimilar competition in oncology.
  • Centene's 2026 antitrust suit over Revlimid settlements threatens damages, scrutiny, and reputational damage.

What makes Bristol Myers Squibb unique

  • Opdivo, Eliquis, and Reblozyl still anchor BMS's diversified revenue engine in 2026.
  • Houston's $2.3 billion campus deepens U.S. manufacturing control across small molecules, biologics, and ADCs.
  • BMS pairs drug development with Nvidia supercomputing and Schrödinger Bunsen for faster discovery cycles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
CultureMap Houston
Aug 11th, 2026
Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory.

Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory. Aug 11, 2026 | 9:00 am New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site. The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park. BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030. "We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release. The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration." "Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region's ability to support a world-class, digitally advanced supply operation," Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. "This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands." Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program. "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare," Abbott said in a news release. "This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers." "Bristol Myers Squibb's announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing," added Greater Houston Partnership President and CEO Steve Kean. Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here. This story was first published on its sister site InnovationMap. all about that base Houston hero JJ Watt sparks new investment in Texas energy startup. Aug 7, 2026 | 10:45 am Houston Texans legend J.J. Watt is an investor in and customer of Austin-based energy startup Base Power. Courtesy of Base Power Since retiring from the NFL three years ago, Houston Texans legend J.J. Watt has been exploring a new field - investing. In 2023, the former defensive end and current CBS Sports football analyst bought a stake in English soccer team Burnley FC. A year later, he invested in the PopUp Bagels chain. This summer, Watt made what may be his highest-profile investment yet. He contributed to a $1 billion Series D round for Austin-based energy startup Base Power, which has an office in Houston. It's Watts' first investment in the energy sector. "I like companies that solve real problems, and Base is lowering power bills, protecting families, and building the whole thing themselves right here in Texas," Watt said in a company news release. "What impressed me wasn't just how fast they've grown," he adds. "It's that they've already saved Texans millions on their power bills and kept thousands of homes running when the lights went out. That's why I invested." Base Power is building a distributed network of residential batteries that's designed to strengthen the grid and lower electrical bills. The startup now powers more than 30,000 homes in Texas, including the Houston area, and recently expanded to Illinois. Base Power's $1 billion round lifted its valuation to $13 billion. Since being founded in 2023, the startup has raised more than $2.5 billion. "JJ is a legend in this state, and he earned that as much for how he shows up off the field as for what he did on it," says Zach Dell, co-founder and CEO of Base Power. "He spent a full day with us asking every hard question he could think of, and then he switched to Base himself. We're glad to have him partnering with us." Zach Dell is the only son of Austin billionaire Michael Dell, chairman and CEO of Round Rock-based Dell Technologies. Michael Dell grew up in Bellaire. This story was first published on its sister site EnergyCapitalHTX.

Yahoo Finance
Aug 10th, 2026
Bristol Myers Squibb to build $2.3B Houston drug manufacturing campus

Bristol Myers Squibb will build a $2.3 billion drug manufacturing campus in Houston, Texas, as part of its $40 billion US investment commitment over five years. The 600,000-square-foot facility at Generation Park will produce small molecules, biologics, and antibody-drug conjugates. The campus will employ nearly 500 people in operations, production, engineering, quality control, and administration. Construction is expected to support roughly 2,000 workers through 2030 before operations fully launch. Texas Governor Greg Abbott announced Bristol Myers is eligible for a $4.89 million grant through the Texas Enterprise Fund. The company selected Houston after evaluating multiple markets, citing workforce availability in life sciences, incentives, and infrastructure proximity. Bristol Myers raised its full-year revenue forecast to approximately $49 billion to $50 billion earlier this year.

Texas Border Business
Aug 10th, 2026
Bristol Myers Squibb expands in Houston with $2.3 billion facility and 500 new jobs.

Bristol Myers Squibb expands in Houston with $2.3 billion facility and 500 new jobs. Aug 10, 2026 Listen to article (english) Audio Player Translate text to Spanish or other 102 languages! Jul 7, 2026 Jun 26, 2026 Jun 12, 2026 - Advertisement - Texas Border Business - Advertisement - AUSTIN - Governor Greg Abbott announced Bristol Myers Squibb (NYSE: BMY) will establish a new pharmaceutical manufacturing campus in Houston, with a capital investment of approximately $2.3 billion that will create nearly 500 new jobs. A Texas Enterprise Fund (TEF) grant of $4.89 million has been extended to Bristol Myers Squibb. The expansion is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program. "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare," said Governor Abbott. "This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers." Bristol Myers Squibb is a New Jersey-based global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. - Advertisement - "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," said Bristol Myers Squibb Board Chair and CEO Christopher Boerner, Ph.D. "As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life." "We proudly welcome Bristol Myers Squibb, another leading global pharmaceutical company, to Generation Park," said Generation Park Management District Executive Director Jennifer Mott. "This highly competitive process validates the role our site plays as a vital life science asset both in Texas and nationally. Our commitment to critical investments in infrastructure and a curated ecosystem continues to attract high-value industry clusters that drive long-term prosperity for the region." "Sheldon Independent School District is excited about the opportunities Bristol Myers Squibb will create for student success and future career pathways," said Sheldon ISD Superintendent Dr. Demetrius McCall. "Investments like this help connect classroom learning to real-world opportunities, preparing our students to thrive in a rapidly growing and innovative economy. We believe the impact of this project will open doors for generations of students and families for many years to come." "Bristol Myers Squibb's announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing," said Greater Houston Partnership President and CEO Steve Kean. "Supported by world-class talent, infrastructure, and industry expertise, this investment will create hundreds of high-quality jobs and strengthen Houston's standing as a leading hub for life sciences innovation and investment." - Advertisement - TEF is a performance-based grant, administered by the Texas Economic Development & Tourism Office within the Office of the Governor, that may be awarded to a business relocation or expansion project for which one Texas site is in competition with out-of-state locations to create new, good-paying jobs in the community and attract significant new capital investment to the state. Governor Abbott signed House Bill 5 into law following the 88th Regular Legislative Session, creating the JETI program to attract large, capital-intensive economic development projects that bring new capital investment and create new, good-paying Texas jobs while ensuring robust reporting and transparency. - Advertisement - Aug 10, 2026

Yahoo Finance
Aug 7th, 2026
BMS claims pharma's most powerful supercomputer with Nvidia, beating Lilly and Roche

Bristol Myers Squibb announced an expanded partnership with Nvidia to build what it claims will be "the most powerful and energy-efficient single-owned Nvidia infrastructure in life sciences". BMS joins Eli Lilly and Roche in staking supercomputer superlative claims, though companies use different metrics to measure power. According to Nvidia, BMS' planned system will be the most advanced by operations per second, whilst others measure by GPU count or single system capacity. The companies are pursuing greater computing power to train larger models, run more complex experiments, and accelerate drug discovery. BMS has worked with Nvidia for nearly three years. The company previously used AI to overcome a plateau whilst searching for a clinical candidate for a sickle cell programme. Under the expanded deal, BMS will deploy Nvidia's DGX SuperPOD supercomputer, delivering up to ten times greater performance per megawatt than its predecessor.

Yahoo Finance
Aug 5th, 2026
Bristol Myers Squibb deploys Schrödinger's AI co-scientist Bunsen for drug discovery

Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.

INACTIVE